Clinical Trial Update: Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial final update evaluating blinatumomab in adult patients with minimal residual disease in B-precursor acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Goethe University | Conditions: ALL, Recurrent, Adult | Phase 2 | Status: COMPLETED